Rhone-Poulenc 1st Qtr 1996 Income Declines 13.5%

5 May 1996

As previously forecast by the company, Rhone-Poulenc saw first-quarter 1996 net income fall 13.5% to 633 million French francs ($122.8 million), largely as a result of interest expenses and amortization of goodwill following the acquisition of Fisons last October. Synergies from this deal are not expected to be realized until the second half of the year.

Group sales were also down, by 1.8%, to 21.13 billion francs ($4.1 billion), pulled back by fibers, polymers and chemicals, which suffered from adverse economic conditions, particularly in Brazil in the area of polyester.

However, the group's health care businesses brought in turnover of 9.15 billion francs, up 3.7% on the like, year-earlier period, with volume sales 5.4% higher. Currency factors had a negative influence of 1.5% and price decline of 0.2%, R-P noted. Operating income from health care was 902 million francs, down 4.9%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight